Photo of Simo Arredouani,  PhD

Simo Arredouani, PhD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 735-2102
Fax: (617) 735-2117


marredou@bidmc.harvard.edu

Simo Arredouani, PhD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Surgery, Harvard Medical School
  • Staff Ph.D., Surgery, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research revolves around tumor immunology and immunotherapy, with a special emphasis on exploring pathophysiological mechanisms driving immune tolerance to prostate tumor antigens and pre-clinically implementing novel cancer immunotherapy platforms. I am especially interested in the concept of combinatorial immunotherapy, which tests the translation potential of new breakthroughs in immune tolerance into efficient immunotherapeutic strategies in conjunction with cancer vaccines. This encompasses accurate targeting of tumors by the immune system through identification of highly specific tumor antigens and finding new ways to interfere with inhibitory mechanisms that compromise immune surveillance in cancer. Additionally, I am actively involved in several ongoing collaborative efforts with investigators within and outside the Harvard Medical School system. Examples include targeting NKT for cancer immunotherapy, manipulation of T cell and DC metabolome to modulate anti-tumor immunity, and identification of novel, putative tumor-specific markers that could serve as immunotherapy targets. Using the studies described above as a foundation, I envision my program expanding into other aspects of tumor immunology as a method of advancing our knowledge of tumor-immune interaction and identifying strategies to harness the new findings towards novel, more effective immunotherapies.

Publications

Powered by Harvard Catalyst
  • Kissick HT, Sanda MG, Dunn LK, Pellegrini KL, On ST, Noel JK, Arredouani MS. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci U S A 2014; 111:9887-9892. PubMed
  • Arredouani MS, Bhasin MK, Sage D, Dunn LK, Gill MB, Agnani D, Libermann TA, Fingeroth J. Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the Epstein-Barr virus receptor/CD21 in B-cell maturation, activation and initiation of virus infection. J Virol 2014. PubMed
  • Kissick HT, Sanda MG, Dunn LK, Arredouani MS. Immunization with a Peptide Containing MHC Class I and II Epitopes Derived from the Tumor Antigen SIM2 Induces an Effective CD4 and CD8 T-Cell Response. PLoS ONE 2014; 9:e93231. PubMed
  • Kissick HT, Sanda MG, Dunn LK, Arredouani MS. Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer. Cancer Immunol Immunother 2013; 62:1831-40. PubMed
  • Lu B, Asara JM, Sanda MG, Arredouani MS. The role of the transcription factor SIM2 in prostate cancer. PLoS ONE 2011; 6:e28837. PubMed
  • Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, Escara-Wilke J, Leander KR, Defeo-Jones D, Hwang C, Sanda MG. Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate 2010; 70:1002-11. PubMed
  • Nowak M, Arredouani MS, Tun-Kyi A, Schmidt-Wolf I, Sanda MG, Balk SP, Exley MA. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide. PLoS ONE 2010; 5:e11311. PubMed
  • Galicia G, Maes W, Verbinnen B, Kasran A, Bullens D, Arredouani M, Ceuppens JL. Haptoglobin deficiency facilitates the development of autoimmune inflammation. Eur J Immunol 2009; 39:3404-12. PubMed
  • Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA, Sanda MG. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res 2009; 15:5794-802. PubMed
  • Hmadcha A, Abdelkrim H, Domínguez-Bendala J, Juan DB, Wakeman J, Jane W, Arredouani M, Mohamed A, Soria B, Bernat S. The immune boundaries for stem cell based therapies: problems and prospective solutions. J Cell Mol Med 2009; 13:1464-75. PubMed
  • Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, Sanda MG. A safety-modified SV40 Tag developed for human cancer immunotherapy. Drug Des Devel Ther 2009; 2:17-24. PubMed
  • Haram KM,Peltier HJ,Lu B,Bhasin M,Otu HH,Choy B,Regan M,Libermann TA,Latham GJ,Sanda MG,Arredouani MS. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. Prostate 2008; 68:1517-30. PubMed
  • Tseng-Rogenski SS, Arredouani MS, Neeley YC, Lu B, Chinnaiyan AM, Sanda MG. Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer. Cancer Immunol Immunother 2008; 57:1357-65. PubMed
  • Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy. Prostate 2008; 68:715-27. PubMed
  • Limmon GV, Arredouani M, McCann KL, Corn Minor RA, Kobzik L, Imani F. Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA. FASEB J 2008; 22:159-67. PubMed
  • Arredouani MS, Franco F, Imrich A, Fedulov A, Lu X, Perkins D, Soininen R, Tryggvason K, Shapiro SD, Kobzik L. Scavenger Receptors SR-AI/II and MARCO Limit Pulmonary Dendritic Cell Migration and Allergic Airway Inflammation. J Immunol 2007; 178:5912-20. PubMed
  • Dahl M, Bauer AK, Arredouani M, Soininen R, Tryggvason K, Kleeberger SR, Kobzik L. Protection against inhaled oxidants through scavenging of oxidized lipids by macrophage receptors MARCO and SR-AI/II. J Clin Invest 2007; 117:757-64. PubMed
  • Lim RH, Arredouani MS, Fedulov A, Kobzik L, Hubeau C. Maternal allergic contact dermatitis causes increased asthma risk in offspring. Respir Res 2007; 8:56. PubMed
  • Arredouani MS, Yang Z, Imrich A, Ning Y, Qin G, Kobzik L. The macrophage scavenger receptor SR-AI/II and lung defense against pneumococci and particles. Am J Respir Cell Mol Biol 2006; 35:474-8. PubMed
  • Józefowski S, Sulahian TH, Arredouani M, Kobzik L. Role of scavenger receptor MARCO in macrophage responses to CpG oligodeoxynucleotides. J Leukoc Biol 2006; 80:870-9. PubMed
  • Józefowski S, Arredouani M, Sulahian T, Kobzik L. Disparate regulation and function of the class A scavenger receptors SR-AI/II and MARCO. J Immunol 2005; 175:8032-41. PubMed
  • Arredouani MS, Palecanda A, Koziel H, Huang YC, Imrich A, Sulahian TH, Ning YY, Yang Z, Pikkarainen T, Sankala M, Vargas SO, Takeya M, Tryggvason K, Kobzik L. MARCO is the major binding receptor for unopsonized particles and bacteria on human alveolar macrophages. J Immunol 2005; 175:6058-64. PubMed
  • De Vleeschouwer S, Arredouani M, Adé M, Cadot P, Vermassen E, Ceuppens JL, Van Gool SW. Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells. Cancer Immunol Immunother 2005; 54:372-82. PubMed
  • Arredouani MS, Kasran A, Vanoirbeek JA, Berger FG, Baumann H, Ceuppens JL. Haptoglobin dampens endotoxin-induced inflammatory effects both in vitro and in vivo. Immunology 2005; 114:263-71. PubMed
  • Arredouani M, Yang Z, Ning Y, Qin G, Soininen R, Tryggvason K, Kobzik L. The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles. J Exp Med 2004; 200:267-72. PubMed
  • Arredouani MS, Kobzik L. The structure and function of marco, a macrophage class a scavenger receptor. Cell Mol Biol (Noisy-le-grand) 2004; 50 Online Pub:OL657-65. PubMed
  • Arredouani M, Matthijs P, Van Hoeyveld E, Kasran A, Baumann H, Ceuppens JL, Stevens E. Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release. Immunology 2003; 108:144-51. PubMed
  • El-Ghmati SM, Arredouani M, Van Hoeyveld EM, Ceuppens JL, Stevens EA. Haptoglobin interacts with the human mast cell line HMC-1 and inhibits its spontaneous proliferation. Scand J Immunol 2002; 55:352-8. PubMed
  • Arredouani M, Matthys P, Kasran A, Baumann H, Ceuppen JL. Haptoglobin and the Th1/Th2 balance: hints from in vitro and in vivo studies. Redox Rep. 2002; 6:369-71. PubMed
  • Perevozchikov AP, Dizhe EB, Serov SM, Kuryshev VIu, Arredouani M, Parfenova NS, Shavlovskiĭ MM, Nasonkin IO, Drapchinskaia NL, Bondarev IE, Tsarapkina EV, Sukonina VE, Denisenko AD, Gaĭtskhoki VS, Klimov AN. [Expression of the human apolipoprotein A-I gene transferred in vitro into mammalian cells and in vivo into rat liver]. Mol. Biol. (Mosk.) 1997; 31:216-23. PubMed
  • Perevozchikov AP, Kuryshev VIu, Arredouani M, Parfenova NS, Shavlovskiĭ MM, Sukonina VE, Dizhe EB, Orlov SV, Denisenko AD, Gaĭtskhoki VS, Klimov AN. [Directed transfer of the human apolipoprotein A-I gene and bacterial genes-markers into rat liver]. Dokl. Akad. Nauk. 1997; 352:571-4. PubMed
Hide